Humacyte Debt to Equity

Humacyte (HUMA) currently reports a debt-to-equity ratio of 5.67. That is above the Healthcare sector average of 0.93. Use the charts on this page to explore Humacyte's debt-to-equity ratio history and peer comparisons.

Humacyte's debt-to-equity ratio of 5.67 is higher than the Healthcare sector average of 0.93. That is roughly 507.9% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The debt-to-equity ratio is a valuation multiple that relates Humacyte's market price to a fundamental measure such as earnings, sales, or book value. At 5.67, HUMA can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current debt-to-equity ratio of 5.67, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 0.93. From there, open related valuation or income-statement pages for Humacyte, and consider following HUMA for alerts when major investors trade the stock.

Humacyte is classified in the Healthcare sector. On debt-to-equity ratio, it currently shows 5.67 versus a sector average near 0.93. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HUMA with unrelated industries.